Menu

Price Performance Heatmap

5Y Price (Market Cap Weighted)

All Stocks (3759)

Company Market Cap Price
LLY Eli Lilly and Company
Lilly is a large, diversified global pharmaceutical company with a core high-revenue portfolio.
$972.49B
$1053.75
+2.55%
JNJ Johnson & Johnson
Johnson & Johnson's portfolio includes multiple monoclonal antibody therapeutics (e.g., DARZALEX, CARVYKTI, TECVAYLI, TALVEY) across oncology and immunology.
$509.56B
$214.04
+1.16%
ABBV AbbVie Inc.
AbbVie directly commercializes monoclonal antibody therapeutics (e.g., Skyrizi) as a core immunology asset.
$394.51B
$226.96
+1.63%
UNH UnitedHealth Group Incorporated
UNH is primarily a health insurer and provides medical benefit plans through UnitedHealthcare.
$309.60B
$339.79
-0.60%
AZN AstraZeneca PLC
AZN is a large-cap pharmaceutical company with a diversified, global drug portfolio and a robust R&D pipeline.
$278.47B
$91.06
+1.37%
MRK Merck & Co., Inc.
The company markets vaccines (Capvaxive) and has historical Gardasil sales, making vaccines a core product category.
$250.53B
$99.66
-0.64%
NVO Novo Nordisk A/S
Novo Nordisk is a leading large-cap pharmaceutical company with blockbuster GLP-1 products Wegovy and Ozempic, a core driver of its revenue and growth.
$226.31B
$50.38
+0.41%
ABT Abbott Laboratories
Abbott's cardiology device portfolio includes leadless pacemakers (AVEIR), MitraClip/TMVR systems and other interventional devices, representing core revenue drivers in Cardiology Devices.
$218.36B
$128.44
+2.38%
TMO Thermo Fisher Scientific Inc.
Thermo Fisher directly manufactures and sells diagnostic instruments and equipment used in clinical labs.
$216.10B
$567.74
-0.79%
ISRG Intuitive Surgical, Inc.
Intuitive Surgical directly manufactures robotic surgical systems and instruments, i.e., core surgical equipment.
$194.41B
$555.58
+2.45%
AMGN Amgen Inc.
Amgen's portfolio includes monoclonal antibody therapeutics such as Repatha and tezepelumab (TEZSPIRE).
$171.06B
$319.44
+0.54%
DHR Danaher Corporation
Danaher directly sells diagnostic equipment/instruments (e.g., Cepheid and Beckman Coulter diagnostics platforms like DxC 500i, DXi 9000).
$162.06B
$226.42
+0.04%
GILD Gilead Sciences, Inc.
Trodelvy is a TROP2-targeted antibody-drug conjugate (ADC), a core oncology modality.
$149.39B
$120.40
← Previous
1 2 3 ... 38
Next →
Showing page 1 of 38 (3759 total stocks)

Loading company comparison...

Loading research report...

GILD Gilead Sciences, Inc.

Gilead’s New HIV Regimen Meets Primary Endpoint in Phase 3 Trial

Dec 15, 2025
JNJ Johnson & Johnson

FDA Grants Priority Review Voucher to Johnson & Johnson’s CAR‑T Therapy for Relapsed Multiple Myeloma

Dec 15, 2025
JNJ Johnson & Johnson

Johnson & Johnson Secures FDA Approval for AKEEGA in BRCA2‑Mutated Metastatic Castration‑Sensitive Prostate Cancer

Dec 13, 2025
NVO Novo Nordisk A/S

Novo Nordisk Launches Ozempic in India, Targeting a $24‑Per‑Week Price Point

Dec 13, 2025
AMGN Amgen Inc.

Amgen Secures FDA Approval for UPLIZNA in Generalized Myasthenia Gravis, Expanding Rare‑Disease Portfolio

Dec 12, 2025
GILD Gilead Sciences, Inc.

Gilead and Arcus End Phase 3 Trial of Domvanalimab Combination in Advanced Stomach and Esophageal Cancer

Dec 12, 2025
LLY Eli Lilly and Company

EMA Approves Eli Lilly’s Mounjaro for Children 10 and Older

Dec 12, 2025
MRK Merck & Co., Inc.

Merck’s WINREVAIR Receives Positive EU CHMP Opinion for Expanded Pulmonary Arterial Hypertension Indication

Dec 12, 2025
NVO Novo Nordisk A/S

EMA Grants Positive Opinion for Novo Nordisk’s 7.2‑mg Wegovy, Expanding EU Obesity Portfolio

Dec 12, 2025
ISRG Intuitive Surgical, Inc.

Intuitive Surgical Secures FDA Clearance for da Vinci SP in High‑Volume General Surgery Procedures

Dec 11, 2025
LLY Eli Lilly and Company

Eli Lilly Announces Landmark Results from Retatrutide Phase 3 TRIUMPH‑4 Trial

Dec 11, 2025
JNJ Johnson & Johnson

Johnson & Johnson Announces Breakthrough Results from TECVAYLI® + DARZALEX FASPRO® in Phase 3 MajesTEC‑3 Study

Dec 10, 2025
LLY Eli Lilly and Company

Eli Lilly Invests $6 Billion in Alabama Plant to Expand Obesity Drug Production

Dec 10, 2025
MRK Merck & Co., Inc.

Formycon and Zydus Announce Exclusive Licensing Deal for Keytruda Biosimilar FYB206 in U.S. and Canada

Dec 10, 2025
LLY Eli Lilly and Company

Eli Lilly Completes $261 Million Acquisition of Adverum Biotechnologies

Dec 09, 2025
UNH UnitedHealth Group Incorporated

West Virginia Files Lawsuit Against UnitedHealth’s Optum Over Opioid Distribution Practices

Dec 09, 2025
ABBV AbbVie Inc.

AbbVie and OSE Shift Early‑Stage Development of ABBV‑230, Retain Future Commercial Rights

Dec 08, 2025
ABT Abbott Laboratories

Abbott Expands Lingo Continuous Glucose Monitor to Android Devices

Dec 08, 2025
AZN AstraZeneca PLC

AstraZeneca Expands Liquid‑Biopsy Access Partnership to China

Dec 08, 2025
JNJ Johnson & Johnson

Johnson & Johnson Announces Landmark Overall‑Survival Benefit for RYBREVANT®/LAZCLUZE® in Asian NSCLC Patients

Dec 08, 2025
MRK Merck & Co., Inc.

Merck Expands CAPVAXIVE® into Saskatchewan Adult Immunization Program, Boosting Vaccine Division Revenue

Dec 08, 2025
JNJ Johnson & Johnson

Johnson & Johnson Announces Landmark CAR‑T Trial Results, Strengthening Oncology Portfolio

Dec 06, 2025
MRK Merck & Co., Inc.

German Court Grants Halozyme Preliminary Injunction Against Merck’s Keytruda SC

Dec 05, 2025
LLY Eli Lilly and Company

Eli Lilly Secures FDA Approval for Jaypirca in Earlier‑Stage CLL/SLL Indication

Dec 04, 2025
MRK Merck & Co., Inc.

Merck Secures FDA Conditional Approval for New Animal Health Product EXZOLT CATTLE-CA1

Dec 04, 2025
TMO Thermo Fisher Scientific Inc.

Thermo Fisher Expands Bioprocess Design Centers in Asia, Adding Hyderabad Hub

Dec 03, 2025
AMGN Amgen Inc.

Accord Healthcare Launches Denosumab Biosimilars Osvyrti and Jubereq, Challenging Amgen’s Prolia and Xgeva

Dec 02, 2025
AZN AstraZeneca PLC

AstraZeneca Secures FDA Priority Review for Baxdrostat, Accelerating Path to Market

Dec 02, 2025
MRK Merck & Co., Inc.

Merck & Co. Issues $8 B Corporate Bond Offering to Fund Pipeline and Strategic Acquisitions

Dec 02, 2025
JNJ Johnson & Johnson

Johnson & Johnson Secures European Commission Approval for IMAAVY (Nipocalimab) in Generalized Myasthenia Gravis

Dec 01, 2025
MRK Merck & Co., Inc.

Merck Secures FDA Fast Track Designation for Alzheimer’s Candidate MK‑2214, Plans First‑In‑Human Data Presentation at CTAD 2025

Dec 01, 2025
UNH UnitedHealth Group Incorporated

UnitedHealth Group Sells Banmedica to Patria Investments for $1 Billion, Exiting Latin America

Dec 01, 2025
ABBV AbbVie Inc.

AbbVie Secures Canadian Reimbursement Recommendation for SKYRIZI in Ulcerative Colitis

Nov 28, 2025
NVO Novo Nordisk A/S

Novo Nordisk Submits FDA Application for 7.2‑mg Wegovy Dose

Nov 27, 2025
AZN AstraZeneca PLC

AstraZeneca Receives FDA Approval for IMFINZI Plus FLOT in Early‑Stage Gastric and GEJ Cancers

Nov 26, 2025
NVO Novo Nordisk A/S

Novo Nordisk Reports Strong Phase 2 Results for Amycretin, Paving Way for 2026 Phase 3 Launch

Nov 25, 2025
TMO Thermo Fisher Scientific Inc.

Thermo Fisher Prices €2.1 Billion Senior Notes to Fund Growth and Acquisitions

Nov 25, 2025
ABT Abbott Laboratories

Abbott Launches U.S. Correction for FreeStyle Libre 3 Sensors After Falsely Low Readings Detected

Nov 24, 2025
AZN AstraZeneca PLC

AstraZeneca Expands Strategic Collaboration with Harbour BioMed, Extending Four‑Year Partnership

Nov 24, 2025
NVO Novo Nordisk A/S

Novo Nordisk’s Oral Semaglutide Alzheimer’s Trials Fail to Meet Primary Endpoint

Nov 24, 2025
AZN AstraZeneca PLC

AstraZeneca Invests $2 Billion to Expand Maryland Manufacturing, Targeting Rare‑Disease Production

Nov 22, 2025
MRK Merck & Co., Inc.

Merck Gains FDA Approval for Pembrolizumab‑Based Combination to Treat Cis‑Platin‑Ineligible Bladder Cancer

Nov 22, 2025
NVO Novo Nordisk A/S

Novo Nordisk Partners with Waltz Health to Launch Direct‑to‑Employer Sales Channel for GLP‑1 Drugs

Nov 22, 2025
AZN AstraZeneca PLC

AstraZeneca’s Alexion Unit Secures FDA Approval for Koselugo in Adult NF1 Patients

Nov 21, 2025
LLY Eli Lilly and Company

Eli Lilly Becomes First Drugmaker to Reach $1 Trillion Market Capitalization

Nov 21, 2025
ABT Abbott Laboratories

Abbott Announces $21 B Acquisition of Exact Sciences, Strengthening Cancer Diagnostics Portfolio

Nov 20, 2025
MRK Merck & Co., Inc.

Merck Reports Positive Phase 3 Results for Two‑Drug HIV Regimen; FDA Accepts NDA

Nov 20, 2025
TMO Thermo Fisher Scientific Inc.

Thermo Fisher Secures FDA Approval for Oncomine Dx Target Test as Companion Diagnostic for Bayer’s New HER2‑Directed Lung Cancer Therapy

Nov 20, 2025
ABBV AbbVie Inc.

AbbVie Secures Full FDA Approval for EPKINLY + Rituximab/Lenalidomide in Relapsed Follicular Lymphoma

Nov 19, 2025
LLY Eli Lilly and Company

Eli Lilly Opens 44,000‑Square‑Foot Gateway Labs Site in Philadelphia

Nov 19, 2025